

Mathematical Translation of Metabolic Syndrome: Assessment of siMS Score for Metabolic Syndrome and Biochemical Risks

Sikandar Hayat Khan^{1*} , Abdul Raheem Khan², Asif Hashmat³, Roomana Anwar⁴, Rahat Shahid⁵, Tariq Chaudhry⁶

¹Department of Pathology, PNS Hafeez, Islamabad, Pakistan

²Bedford Hospital, NHS, Bedford, UK

³Department of Neurology, Pak Emirates Military Hospital (PEMH), Rawalpindi, Pakistan

⁴Department of Biochemistry, Islamabad Medical & Dental College, Islamabad, Pakistan

⁵Department of Radiology, PNS Hafeez, Islamabad, Pakistan

⁶PNS Hafeez, Islamabad, Pakistan

Email: *sik_cpssp@yahoo.com

How to cite this paper: Khan, S.H., Khan, A.R., Hashmat, A., Anwar, R., Shahid, R. and Chaudhry, T. (2020) Mathematical Translation of Metabolic Syndrome: Assessment of siMS Score for Metabolic Syndrome and Biochemical Risks. *Open Journal of Endocrine and Metabolic Diseases*, 10, 95-106.
<https://doi.org/10.4236/ojemd.2020.107010>

Received: July 1, 2020

Accepted: July 25, 2020

Published: July 28, 2020

Copyright © 2020 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

Background: Metabolic syndrome over decades has undergone multiple diagnostic criteria announced by National Cholesterol Education Program (NCEP), WHO, International Diabetic Federation (IDF) and certain regional criteria. Recently, Soldatovic *et al.* have provided a mathematical model for evaluating metabolic syndrome. We aimed to compare siMS score among subjects with and without metabolic syndrome and other biochemical risks including insulin resistance. **Methods:** The study was conducted at PNS HAFEEZ hospital from July-2017 to Jan-2019. A comparative cross-sectional analysis was carried out among 232 subjects to evaluate siMS score among metabolic syndrome and those without metabolic syndrome. Pearson's correlation was performed for siMS score with other anthropometric and biochemical measures. Finally ROC curve analysis was performed to evaluate various biomarkers along with siMS score for diagnosis of metabolic syndrome. **Results:** Insulin resistance between subjects was higher among subjects with metabolic syndrome [Mean = 3.27 ± 4.45] than non-metabolic syndrome subjects [Mean = 2.10 ± 1.89] ($p = 0.012$). Differences in siMS score was higher in subjects with metabolic syndrome (Mean = 3.58 ± 0.725 , N = 121) than subjects without metabolic syndrome (Mean = 2.83 ± 0.727 , N = 108). AUC for various biochemical parameters was highest for sdLDL cholesterol and siMS score. **Conclusion:** siMS score has shown better performance than HOMAIR, sdLDL cholesterol, non-HDL cholesterol, HbA1c, and fasting plasma glucose in diagnosing metabolic syndrome.

Keywords

siMS Score, HOMA-IR, Metabolic Syndrome, Small Dense LDL-Cholesterol (sdLDL), Non-HDL Cholesterol, HbA1c

1. Introduction

Since the conception of the term “metabolic syndrome” various nomenclatures have been used with multiple criteria. Overtime these criteria were refined into more systematic criteria by various organizations like National Cholesterol Education Program (NCEP), World Health Organization (WHO) and International Diabetic Federation (IDF) [1] [2] [3]. Furthermore, regional criteria for labeling subjects with metabolic syndrome also appear with slight variations [4]. While being useful in many ways, there is a tangible gap between these criteria and lack of mathematically defined cut-off to unify metabolic syndrome. Recently, Soldatovic *et al.* have provided a mathematical model using parameters included in metabolic syndrome, which seems to be promising [5]. However, no local or regional study is available in literature to validate usefulness of this model in our set up.

Insulin resistance:

Why there is a need to have a simplified mathematical model in clinical practice? As highlighted above multiple criteria are there which are overlapping with slightly different cut-offs and parameters which create confusion in routine clinical practice, which may not be providing a unified diagnostic system for patients [6]. Underlying insulin resistance by using insulin-based models HOMAIR is also difficult to measure both due to cost and clinical difficulties in routine practice which makes some of the metabolic syndrome ambiguous in terms of correlation with established metabolic syndrome criteria [7]. An unmet and pushing need therefore arises to have a mathematical defined, easy to a measure and apply criteria for clinical practice.

Earlier attempts to mathematical model metabolic syndrome are also available. Gurka *et al.* have evaluated race or ethnicity specific mathematical model to predict risk in both adult and pediatric population by utilizing a “confirmatory factor analysis” in SAS program [8]. Similarly, Huh *et al.* have suggested a clinically applicable equation for continuous monitoring of metabolic syndrome risk for Korean population [9].

This study aims to evaluate the siMS scores among our sample population identified to have metabolic syndrome or otherwise as per IDF criteria and also to correlate this scoring with various biochemical risk factors including insulin resistance.

2. Methods

Study settings and design: This cross-sectional study was carried out at the

department of medicine and pathology Naval Hospital (Islamabad) in liaison with chemical pathology department at AFIP for analysis of some biochemical parameters. Referrals were also made by neighboring hospital for possible inclusion into study. The study was comparative cross-sectional and was conducted from July-2017 to Jan-2019. The study has the organizational ethical review committee approval and ensured written signed consent for all participants.

Target population & subject selection: All adults visiting hospital for executive annual medical check-up considered as target population. Patient selection was based upon the “non-probability convenience sampling” methodology. Subjects with known metabolic disorder like diabetes, hypertension, ischemic heart disease (IHD), autoimmune disorder or other acute or chronic ailments were excluded from the study. Pregnant subjects were also excluded from the study.

Sampling & general clinical examination: The study participants were requested to visit in medical fasting at the department of pathology around 08:00 to 09:00 hours from Monday to Friday. These patients were explained the medical fasting requirements along with an explanation regarding sampling strategy, purpose of research project and post-results utilization purpose of data. The subjects who finally appeared (N = 232) for study as per conditions explained to them at pathology department were first asked to sign the written consent form. This was followed by a general history and examination to rule any signs of a chronic disease process. After this the phlebotomist collected up to 10 ml of blood from all study subjects for various biochemical parameters including fasting glucose and lipids, HbA1c and insulin in specified containers. A urine sample was collected from 171 subjects for measuring urine albumin creatinine ratio (UACR).

Clinical measurements and analysis: All anthropometric measurements were calculated as per the WHO defined criteria and Guerrero-Romero *et al.* methodology for abdominal volume index (AVI) [10] [11]. Biochemical parameters including cholesterol, triglycerides and glucose were measured by CHOD PAP, GPO PAP and GOD PAP techniques on random access clinical chemistry analyzer (Slectra ProM). HDL and LDL lipoproteins were measured using cholesterol esterase methodology on AVIDA-1800 random access clinical chemistry analyzer. HbA1c was analyzed using ion-exchange resin chromatography method. Serum insulin was analyzed using Immulite® 1000 chemiluminescence analyzer.

Outcome measures:

- Metabolic syndrome and diabetes was diagnosed as per IDF criteria, as:
 - Waist circumference ≥ 94 cm (Males) and ≥ 80 cm (Females), PLUS ANY OF TWO as:
 - HDLc < 1.03 mmol/L (Males) or < 1.3 mmol/L (Females);
 - Triglycerides > 1.7 mmol/L;
 - Blood pressure $> 130/85$ mm of Hg;
 - Fasting glucose 5.6 mmol/L [12] [13].

- siMS score was calculated as per Soldatovic *et al.* formula [5], as described below:

Male:

$$\text{siMS score} = (2 \times \text{Waist/Height}) + (\text{Glucose}/5.6) + (\text{Triglyceride}/1.7) + (\text{TA}_{\text{systolic}}/130) - (\text{HDL}/1.02).$$

Female:

$$\text{siMS score} = (2 \times \text{Waist/Height}) + (\text{Glucose}/5.6) + (\text{Triglyceride}/1.7) + (\text{TA}_{\text{systolic}}/130) - (\text{HDL}/1.28).$$

- HOMA IR was calculated by the formula of Mathew's *et al.* as:

$$\text{HOMA IR} = \left\{ \frac{\text{Serum Insulin (mIU/L)}}{\text{Fasting Plasma Glucose (mmol/L)}} \right\} / 22.5 \text{ [14]}.$$

Quality control & calibration: Internal and external laboratory testing is ensured by both external QC insurance program like “National External Quality Assurance Program Pakistan (NEQAPP)” and internal by regular monitoring and troubleshooting through Westgard’s quality control rules. The usual targets for precision (%CV) and accuracy for both inter and intra batch testing are ensured on regular basis along with documentation of any error.

We lost few samples while processing and could not follow up for serum insulin (N = 4), HbA1c (N = 2), and UACR testing was only done in 174 subjects.

Statistical analysis: All data were added to Excel program and later moved to IBM-SPSS version-24. Age and gender based differences were calculated through descriptive statistics option in SPSS while the gender group wise differences between measured and calculated parameters were carried out through Independent Sample t-statistics. Independent sample t-test was used to see the differences for siMS score and insulin resistance between subjects with and without metabolic syndrome. Bivariate Pearson’s correlation method between various evaluated anthropometric and biochemical risk assessment parameters. ROC curve analysis was used to measure the Area Under Curve (AUC) for various parameters in diagnosis of metabolic syndrome.

3. Results

Out of the total sample size we had 52.4% females and 47.6% males. Gender wise descriptive data is shown in **Table 1** for age, anthropometric indices, biochemical measures and siMS score. Insulin resistance between study subjects is as: Metabolic syndrome subjects: Mean = 3.27 ± 4.45 and non-metabolic syndrome subjects: Mean = 2.10 ± 1.89 ($p = 0.012$) as shown in **Figure 1**. **Figure 2** shows the differences in siMS score to be higher in subjects with metabolic syndrome (Mean = 3.58 ± 0.725 , N = 121) than subjects without metabolic syndrome (Mean = 2.83 ± 0.727 , N = 108) as per IDF defined criteria. Pearson’s correlation between various biochemical risk predictor and siMS score suggests siMS score to be highly correlated with anthropometric, glycemic, lipid indices and insulin resistance than other parameters (**Table 2**). AUC for various parameters for various biochemical parameters include sdLDL cholesterol (AUC = 0.700), non-HDL

Table 1. Gender differences between subjects for various evaluated parameters.

| Parameter | Gender | N | Mean | Std. Deviation | Sig. (2-tailed)* |
|--|--------|-----|-------|----------------|------------------|
| Age (years) | Male | 110 | 47.98 | 11.30 | 0.085 |
| | Female | 122 | 45.27 | 12.42 | |
| Body Mass Index (BMI) | Male | 110 | 25.98 | 4.83 | 0.001 |
| | Female | 122 | 28.18 | 5.36 | |
| Waist to Hip Ratio (WHpR) | Male | 110 | 0.93 | 0.10 | 0.143 |
| | Female | 122 | 0.94 | 0.06 | |
| Waist to Height Ratio (WHtR) | Male | 110 | 0.55 | 0.06 | <0.001 |
| | Female | 122 | 0.60 | 0.07 | |
| Abdominal Volume Index (AVI) | Male | 110 | 17.48 | 3.72 | 0.087 |
| | Female | 122 | 18.39 | 4.25 | |
| Fasting Plasma Glucose (mmol/L) | Male | 110 | 5.86 | 2.61 | 0.127 |
| | Female | 122 | 5.41 | 1.87 | |
| Total Cholesterol (mmol/L) | Male | 110 | 4.54 | 0.59 | 0.173 |
| | Female | 122 | 4.43 | 0.62 | |
| Non-HDL Cholesterol (mmol/L) | Male | 110 | 3.63 | 0.58 | 0.009 |
| | Female | 122 | 3.41 | 0.68 | |
| Small Dense LDL (sdLDL) as mmol/L | Male | 110 | 0.82 | 0.35 | 0.676 |
| | Female | 122 | 0.80 | 0.35 | |
| HbA1c (%) | Male | 108 | 5.60 | 1.01 | 0.017 |
| | Female | 120 | 5.91 | 0.93 | |
| Homeostasis Model Assessment for Insulin Resistance (HOMAIR) | Male | 108 | 2.47 | 2.80 | 0.188 |
| | Female | 120 | 3.14 | 4.60 | |
| Urine Albumin Creatinine Ratio (UACR) | Male | 75 | 2.31 | 2.47 | 0.314 |
| | Female | 99 | 3.07 | 6.12 | |
| siMS Score | Male | 110 | 3.23 | 0.88 | 0.980 |
| | Female | 122 | 3.23 | 0.75 | |

*Independent Sample t-test.

Table 2. Correlation between non-HDL cholesterol, small dense LDL cholesterol (sdLDLc), fasting plasma glucose (FPG), homeostasis model assessment for insulin resistance (HOMA IR), urine albumin creatinine ratio (UACR) and siMS score.

| | | Non-HDLc | sdLDLc | HbA1c | FPG | HOMA IR | UACR | siMS score |
|------|---------------------|----------|--------|---------|-------|---------|-------|------------|
| BMI | Pearson Correlation | 0.148* | 0.076 | 0.185** | 0.034 | 0.104 | 0.061 | 0.257** |
| | Sig. (2-tailed) | 0.025 | 0.255 | 0.005 | 0.609 | 0.119 | 0.426 | <0.001 |
| | N | 229 | 229 | 226 | 229 | 226 | 172 | 229 |
| WHtR | Pearson Correlation | 0.164* | 0.158* | 0.230** | 0.102 | 0.205** | 0.130 | 0.404** |
| | Sig. (2-tailed) | 0.013 | 0.016 | <0.001 | 0.125 | 0.002 | 0.088 | <0.001 |
| | N | 229 | 229 | 226 | 229 | 226 | 172 | 229 |

Continued

| | | | | | | | | |
|-----------------|----------------------------|---------|---------|---------|---------|---------|---------|---------|
| | Pearson Correlation | 0.214** | 0.194** | 0.201** | 0.128 | 0.212** | 0.073 | 0.429** |
| AVI | Sig. (2-tailed) | 0.001 | 0.003 | 0.002 | 0.053 | 0.001 | 0.341 | <0.001 |
| | N | 229 | 229 | 226 | 229 | 226 | 172 | 229 |
| | Pearson Correlation | 1 | 0.444** | -0.043 | 0.057 | 0.124 | 0.160* | 0.438** |
| Non-HDLc | Sig. (2-tailed) | | <0.001 | 0.518 | 0.392 | 0.062 | 0.036 | <0.001 |
| | N | 229 | 229 | 226 | 229 | 226 | 172 | 229 |
| | Pearson Correlation | 0.444** | 1 | 0.085 | 0.181** | 0.145* | 0.135 | 0.458** |
| SdLDLc | Sig. (2-tailed) | <0.001 | | 0.204 | 0.006 | 0.030 | 0.078 | <0.001 |
| | N | 229 | 229 | 226 | 229 | 226 | 172 | 229 |
| | Pearson Correlation | -0.043 | 0.085 | 1 | 0.568** | 0.312** | -0.016 | 0.410** |
| HbA1c | Sig. (2-tailed) | 0.518 | 0.204 | | <0.001 | <0.001 | 0.838 | <0.001 |
| | N | 226 | 226 | 226 | 226 | 223 | 172 | 226 |
| | Pearson Correlation | 0.057 | 0.181** | 0.568** | 1 | 0.514** | 0.217** | 0.675** |
| FPG | Sig. (2-tailed) | 0.392 | 0.006 | <0.001 | | <0.001 | 0.004 | <0.001 |
| | N | 229 | 229 | 226 | 229 | 226 | 172 | 229 |
| | Pearson Correlation | 0.124 | 0.145* | 0.312** | 0.514** | 1 | 0.000 | 0.507** |
| HOMAIR | Sig. (2-tailed) | 0.062 | 0.030 | <0.001 | <0.001 | | 0.997 | <0.001 |
| | N | 226 | 226 | 223 | 226 | 226 | 171 | 226 |
| | Pearson Correlation | 0.160* | 0.135 | -0.016 | 0.217** | <0.001 | 1 | 0.214** |
| UACR | Sig. (2-tailed) | 0.036 | 0.078 | 0.838 | 0.004 | 0.997 | | 0.005 |
| | N | 172 | 172 | 172 | 172 | 171 | 172 | 172 |

*p-value < 0.05. **p-value < 0.01.




Figure 1. Differences in HOMAIR in subjects with and without metabolic syndrome ($p = 0.012$).




Figure 2. Differences in siMS score in subjects with and without metabolic syndrome ($p < 0.001$).

cholesterol (AUC = 0.647), HbA1c (AUC = 0.644), Fasting plasma glucose (AUC = 0.698), HOMA IR (AUC = 0.629) and siMS score (AUC = 0.866) as depicted in **Figure 3**.

4. Discussion

siMS score appeared promising in terms of mathematical translation of data from various risk biomarkers included in the definition of metabolic syndrome. Our study also confirmed that this mathematical scoring method is highly correlated with insulin resistance along with demonstrating highest area under the curve for diagnosing metabolic syndrome. Using such an index can help add to diagnostics along with its application as a measurable tool to assess the overall improvement or further worsening of the disease in a patient's prognostic monitoring. While being a simple mathematical number, it can provide the combined data from components of metabolic syndrome to simply patient management. However, Soldatovic *et al.*'s as we demonstrated seems to be very useful and in this regard there are few studies which support its use in clinical care [5]. Vukovic *et al.* have evaluated this method in pediatric population with slight modifications to conclude it as an accurate and practical measure in diagnosis of metabolic syndrome in children and adolescence [15]. Similarly, another pediatric study "the CASPIAN-V study" have also highlighted the practical usefulness in both clinics and research programs after comparing it with various principal component analysis, confirmatory component analysis and z-scores [16].

Provided clinical utility some researchers have highlighted some issues which may not be specific to siMS score, but still needs to be highlighted while using siMS score as a biomarker for metabolic syndrome. Srećković *et al.* have shown




Figure 3. Receiver operating curve (ROC) curve analysis showing area under curve (AUC) for siMS score, HOMA1R, Fasting plasma glucose, HbA1c, non-HDL cholesterol and small dense LDL cholesterol (sdLDLc).

that certain acute phase reactants and cardiovascular disease (CVD) indicators like C-Reactive protein (CRP), Fibrinogen, acidum uricum, Apo-B lipoprotein and homocysteine can confound the siMS score risk prediction [17]. Furthermore Sebekova *et al.* have shown that real-time application of siMS score may label some of the subjects without criterion defined metabolic syndrome to have numerical results falling in the range of metabolic syndrome, thus can result in some false positive cases [18]. However, in the opinion of authors we agree with these later findings as metabolic risk clustering with emerging evidence is ever evolving field and more and newer CVD biomarkers depictive of underlying inflammation and atherosclerotic plaque behavior are now entering clinical market [19]. Moreover, the role of genetics and epigenetics in the absence or presence of metabolic syndrome label, as per the newer evidence is probably more informative in risk prediction than simply quantifying biochemical risk predictor [20] [21].

The study has few limitations. The authors attempted to replicate the use of siMS score in our population; however our sample size was small and the study was hospital based so a larger study in an epidemiological set up may be carried out for validating the siMS score equation for primary care set up. Moreover, as per the findings of Sebekova *et al.* we feel metabolic syndrome could have multifactorial etiology beyond what we have included in our study which thus raises the need of other factors which could lead to false negative low siMS score in the presence of a metabolic syndrome. Clinical assessment therefore must be personalized and this consideration must remain in the mind of treating physicians.

The study has significant clinical implications: The authors consider the use of

siMS score evaluation could provide a real-time assessment model for primary care physician who can not only use this equation as “Rule In” investigation for metabolic syndrome, which can also be used to monitor the treatment and assessment of prognosis for patients. Furthermore the mathematical equation may also be incorporated in hospital information system so as to calculate by the IT system to allow its simplistic application for both patients and physicians.

5. Conclusion

siMS score has shown better performance than HOMAIR, sdLDL cholesterol, non-HDL cholesterol, HbA1c, and fasting plasma glucose in diagnosing metabolic syndrome. Furthermore, the siMS score equation has moderate to high correlation with most of the anthropometric, biochemical and hormonal risk factors.

Declarations

Ethical approval: The study “Mathematical translation of metabolic syndrome by using siMS score: Assessment of siMS score for metabolic syndrome and biochemical risks” was formally approved by hospital’s ethical review committee.

We confirm that our research work conforms to “World Medical Association’s Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects”

Signing of inform consent by participants: All subjects were required to sign the written informed consent before inclusion into study program. All included subjects were explained about the research requirements and use of data along with confidentiality issues.

Availability of SPSS data & outputs: Subject data can be provided on formal request.

Author’s Contributions

SHK: (Author for correspondence) Study idea, study conceptualization, Diagnostic lab analysis, Manuscript writing, Study finalization. **ARK:** Study sampling, analysis of data, manuscript writing. **AH:** Patient selection, examination, referrals, data output (SPSS) analysis, data analysis and manuscript writing. **RA:** Clinical evaluation of patient, statistical methods application & analysis, manuscript writing. **RS:** Sampling collection, data analysis, contribution to manuscript write up. **TC:** Overall study coordination, medical writing, study finalization. All study authors approved the final manuscript version and agreed to all aspects of contents.

Data Funding

There is no funding source to declare.

Acknowledgements

The authors want to acknowledge assistance provided by Lab technician Ibrahim

and Iftikhar.

Conflicts of Interest

Authors have no competing interests to announce.

References

- [1] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*, **285**, 2486-2497. <https://doi.org/10.1001/jama.285.19.2486>
- [2] Alberti, K.G. and Zimmet, P.Z. (1998) Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation. *Diabetic Medicine*, **15**, 539-553. [https://doi.org/10.1002/\(SICI\)1096-9136\(199807\)15:7%3C539::AID-DIA668%3E3.0.CO;2-S](https://doi.org/10.1002/(SICI)1096-9136(199807)15:7%3C539::AID-DIA668%3E3.0.CO;2-S)
- [3] Herath, H.M.M., Weerasinghe, N.P., Weerathna, T.P. and Amarathunga, A.A. (2018) Comparison of the Prevalence of the Metabolic Syndrome among Sri Lankan Patients with Type 2 Diabetes Mellitus Using WHO, NCEP-ATP III, and IDF Definitions. *International Journal of Chronic Diseases*, **2018**, Article ID: 7813537. <https://doi.org/10.1155/2018/7813537>
- [4] Yamagishi, K. and Iso, H. (2017) The Criteria for Metabolic Syndrome and the National Health Screening and Education System in Japan. *Epidemiology and Health*, **39**, e2017003. <https://doi.org/10.4178/epih.e2017003>
- [5] Soldatovic, I., Vukovic, R., Culafic, D., Gajic, M. and Dimitrijevic-Sreckovic, V. (2016) siMS Score: Simple Method for Quantifying Metabolic Syndrome. *PLoS ONE*, **11**, e0146143. <https://doi.org/10.1371/journal.pone.0146143>
- [6] Reuter, C.P., Burgos, M.S., Barbian, C.D., Renner, J.D.P., Franke, S.I.R. and De Mello, E.D. (2018) Comparison between Different Criteria for Metabolic Syndrome in Schoolchildren from Southern Brazil. *European Journal of Pediatrics*, **177**, 1471-1477. <https://doi.org/10.1007/s00431-018-3202-2>
- [7] Kang, E.S., Yun, Y.S., Park, S.W., Kim, H.J., Ahn, C.W., Song, Y.D., *et al.* (2005) Limitation of the Validity of the Homeostasis Model Assessment as an Index of Insulin Resistance in Korea. *Metabolism*, **54**, 206-211. <https://doi.org/10.1016/j.metabol.2004.08.014>
- [8] Gurka, M.J., Ice, C.L., Sun, S.S. and Deboer, M.D. (2012) A Confirmatory Factor Analysis of the Metabolic Syndrome in Adolescents: An Examination of Sex and Racial/Ethnic Differences. *Cardiovascular Diabetology*, **11**, Article No. 128. <https://doi.org/10.1186/1475-2840-11-128>
- [9] Huh, J.H., Lee, J.H., Moon, J.S., Sung, K.C., Kim, J.Y. and Kang, D.R. (2019) Metabolic Syndrome Severity Score in Korean Adults: Analysis of the 2010-2015 Korea National Health and Nutrition Examination Survey. *Journal of Korean Medical Science*, **34**, e48. <https://doi.org/10.3346/jkms.2019.34.e48>
- [10] National Health and Nutrition Examination Survey (NHANES). Anthropometry Procedures Manual. https://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/manual_an.pdf
- [11] Guerrero-Romero, F. and Rodríguez-Morán, M. (2003) Abdominal Volume Index.

- An Anthropometry-Based Index for Estimation of Obesity Is Strongly Related to Impaired Glucose Tolerance and Type 2 Diabetes Mellitus. *Archives of Medical Research*, **34**, 428-432. [https://doi.org/10.1016/S0188-4409\(03\)00073-0](https://doi.org/10.1016/S0188-4409(03)00073-0)
- [12] Alberti, K.G., Zimmet, P., Shaw, J. and IDF Epidemiology Task Force Consensus Group (2005) The Metabolic Syndrome—A New Worldwide Definition. *The Lancet*, **366**, 1059-1062. [https://doi.org/10.1016/S0140-6736\(05\)67402-8](https://doi.org/10.1016/S0140-6736(05)67402-8)
- [13] American Diabetes Association (2018) 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes-2018*. *Diabetes Care*, **41**, S13-S27. <https://doi.org/10.2337/dc18-S002>
- [14] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. and Turner, R.C. (1985) Homeostasis Model Assessment: Insulin Resistance and Beta-Cell Function from Fasting Plasma Glucose and Insulin Concentrations in Man. *Diabetologia*, **28**, 412-419. <https://doi.org/10.1007/BF00280883>
- [15] Vukovic, R., Milenkovic, T., Stojan, G., Vukovic A, Mitrovic K, Todorovic, S. and Soldatovic, I. (2017) Pediatric siMS score: A New, Simple and Accurate Continuous Metabolic Syndrome Score for Everyday Use in Pediatrics. *PLoS ONE*, **12**, e0189232. <https://doi.org/10.1371/journal.pone.0189232>
- [16] Khoshhali, M., Heshmat, R., Esmaeil Motlagh, M., Ziaodini, H., Hadian, M., Aminaei, T., et al. (2019) Comparing the Validity of Continuous Metabolic Syndrome Risk Scores for Predicting Pediatric Metabolic Syndrome: The CASPIAN-V Study. *Journal of Pediatric Endocrinology and Metabolism*, **32**, 383-389. <https://doi.org/10.1515/jpem-2018-0384>
- [17] Srečković, B., Soldatovic, I., Colak, E., Mrdovic, I., Sumarac-Dumanovic, M., Janeski, H., et al. (2018) Homocysteine Is the Confounding Factor of Metabolic Syndrome-Confirmed by siMS Score. *Drug Metabolism and Personalized Therapy*, **33**, 99-103. <https://doi.org/10.1515/dmpt-2017-0013>
- [18] Sebekova, K. and Sebek, J. (2018) Continuous Metabolic Syndrome Score (siMS) Enables Quantification of Severity of Cardiometabolic Affliction in Individuals Not Presenting with Metabolic Syndrome. *Bratislavské Lekárske Listy*, **119**, 675-678. https://doi.org/10.4149/BLL_2018_121
- [19] Murillo-González, F.E., Ponce-Ruiz, N., Rojas-García, A.E., Rothenberg, S.J., Bernal-Hernández, Y.Y., Cerda-Flores, R.M., et al. (2019) PON1 Lactonase Activity and Its Association with Cardiovascular Disease. *Clinica Chimica Acta*, **500**, 47-53.
- [20] Zhang, W.H., Xin, L.L. and Lu, Y. (2017) Integrative Analysis to Identify Common Genetic Markers of Metabolic Syndrome, Dementia, and Diabetes. *Medical Science Monitor*, **23**, 5885-5891. <https://doi.org/10.12659/MSM.905521>
- [21] Stols-Gonçalves, D., Tristão, L.S., Henneman, P. and Nieuwdorp, M. (2019) Epigenetic Markers and Microbiota/Metabolite-Induced Epigenetic Modifications in the Pathogenesis of Obesity, Metabolic Syndrome, Type 2 Diabetes, and Non-Alcoholic Fatty Liver Disease. *Current Diabetes Reports*, **19**, Article No. 31 <https://doi.org/10.1007/s11892-019-1151-4>

Abbreviations

Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), siMS Score, Small Dense Low Density Lipoprotein Cholesterol (sdLDLc), Urine Albumin Creatinine Ratio (UACR), Body Mass Index (BMI), Waist to Hip Ratio (WHpR), Waist to Height Ratio (WHtR), Abdominal Volume Index (AVI)